CI Forensic analysis

1. Trading Setup & Entry Strategy

• >Entry Zone: Initiate 30% position at $288.00–$290.00 (retest of the 10-day SMA). Add 40% at $276.00 (on a pullback to the 50-day SMA if the market corrects). Hold final 30% for momentum confirmation.
• >Stop Loss: $273.50 (hard stop below the 50-day SMA support floor).
• >Take Profit: Target 1: $300.00 (Bollinger Upper Band test); Target 2: $315.00 (Upside extension).
• >Position Size: 3% of portfolio.
• >Risk/Reward: 1:2.8 R/R.

2. Executive Summary

Cigna (CI) shows strong bullish momentum following an upward revision of 2026 EPS guidance to >$30.35. Despite an insider sale of $59M reported on May 14th, the technical setup is constructive with a Bullish Crossing trend. With $2.36B in operating income for Q1 2026, the company demonstrates solid cash generation. Rating: BUY on current technical strength.

---

3. Recent Material Events (8-K Analysis)

Recent filings (April/May 2026) confirm the company is optimizing its capital structure and executing on dividend commitments, including a $1.56/share dividend declared in late April. The focus remains on integration of post-HCSC transaction systems.

4. Insider Trading Activity

Recent Form 4s indicate significant selling activity, specifically a $59.11M liquidation on May 14th. While large, this often reflects pre-planned 10b5-1 selling cycles rather than a lack of confidence, but it warrants caution against chasing at the high end of the range.

5. Current News & Market Context

• >Guidance Boost: Raising EPS guidance to >$30.35 is a major catalyst supporting the current price action.
• >Market Sentiment: Neutral to bullish; the broader sector is experiencing volatility due to inflation, but CI is viewed as a steady-growth defensive play.

6. Financial Health & Forensic Flags

• [WARN]Revenue Quality: Evernorth remains the primary growth engine. The company has a robust balance sheet with $7.04B in cash. Flag: High goodwill ($45.5B) necessitates monitoring for impairment risks if synergies underperform.
• >Cash Conversion: Operating cash flow of $1.13B for Q1 reflects typical seasonal headwinds but remains stable.

7. Technical Analysis & Trade Timing

• >Trend: Bullish cross confirmed. Price sits at $291.28, slightly above the 10-day SMA ($290.05) and well above the 50-day ($275.96).
• >Indicators: RSI at 56.01 is neutral, leaving significant room for an upside move before reaching overbought territory (>70).
• >Reconciliation: Fundamentals support the EPS guidance hike; technicals show room to run. We respect the 50-day SMA as the ultimate line in the sand.

8. Investment Recommendation

Thesis: Cigna is a high-conviction value-growth hybrid. The upward EPS guidance shift provides a fundamental floor, while technical momentum is accelerating. We prioritize building a position on any weakness toward the $280-$290 range to optimize risk-adjusted returns.